Selling pressure pushes GSK stock lower in today's trading

Traders Union
All News
Financial News
GSK slides 2.69% today to GBX1,861.50

Highlights

GSK completed a buyback of over 1.6 million shares, boosting treasury holdings and adjusting total voting rights to 4.05 billion.
GSK agreed to acquire Nuvalent for $10.6 billion to strengthen its lung cancer pipeline and support long-term revenue growth.
The stock faces short-term selling pressure, trading below key averages, with an expected five-day range of GBX1,819.90–1,923.90 and a bias for sideways movement.

Share buyback and Nuvalent deal shape capital return amid weak price action

GSK completed a repurchase of over 1.6 million ordinary shares in early June 2026 as part of its ongoing share buyback programme, increasing its treasury holdings to 267.6 million shares and adjusting the total voting rights to 4.05 billion. This buyback contributes to the company's strategy to return capital to shareholders and maintain future flexibility for corporate purposes. Separately, GSK agreed to acquire cancer treatment company Nuvalent for $10.6 billion to expand its lung cancer portfolio and support long-term revenue targets, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees GSK under clear short- and medium-term pressure as the price remains below both the 20-day and 50-day moving averages. He notes that today's negative price action and multiple momentum indicators (MACD, RSI, BBP) reinforce a cautious technical outlook. The recent buyback and Nuvalent acquisition do little to offset the downtrend, highlighting persistent selling interest and weak sentiment. Kharitonov remains skeptical about a near-term reversal with volatility and intraday tone still heavy. He warns: "Until GSK breaks above the key resistance and confirms renewed buyer interest, the risk of further declines should not be underestimated."

Viktoras Karapetjanc, expert at Traders Union, views GSK's strategic moves as a foundation for future growth. He points out the robust share buyback and Nuvalent acquisition, which enhance capital flexibility and diversify the oncology pipeline. Karapetjanc sees the recent pullback as a setup for renewed accumulation, especially with the price holding above the 200-day moving average. The bullish structure on the weekly chart supports further upside if resistance at GBX1,882 is reclaimed. "I see opportunity building for GSK — the broader trend and sound fundamentals favor a positive reassessment by the market," he states.

Selling pressure persists as technical boundaries and negative momentum converge

GSK trades below the 20-day moving average (GBX1,889.75) and the 50-day (GBX1,985.34), but remains above the 200-day (GBX1,846.73), signaling ongoing short- and medium-term selling pressure against a backdrop of stronger long-term support. On the daily timeframe, the nearest resistance is seen near the Ichimoku Kijun at GBX1,882, with the 200-day moving average providing close support.

Momentum signals are weak, with the MACD flashing a strong sell and the Average Directional Index (ADX) indicating active trend pressure in a bearish direction. The Relative Strength Index (RSI) is pointed lower, and both the Stochastic RSI and Commodity Channel Index (CCI) highlight overbought conditions, suggesting the risk of further downside. Bull/Bear Power (BBP) shows sellers dominate intraday momentum, echoing the current overbought reading, while the Awesome Oscillator neutrally aligns with the short-term trend. GSK fell GBX51.50 or 2.69% so far today, opening with a downside gap of about GBX16.78. The stock trades near the daily low, and intraday volatility stands at 2.24%. Intraday tone is heavy with pressure seen after the open, and this aligns with the overall negative momentum signals.

Previously it was reported that GSK was pursuing a major acquisition of Nuvalent to bolster its oncology pipeline and drive long-term growth. With the Nuvalent deal now finalized amid continued short-term selling pressure, traders should watch for any upside momentum if shares can decisively reclaim resistance above GBX1,882 in the days ahead.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.